Neurogenic Orthostatic Hypotension in Multiple System Atrophy — Treatment
Multiple system atrophy commonly involves autonomic dysfunction, and neurogenic orthostatic hypotension is a clinically significant manifestation that requires structured pharmacologic management.
Clinical scenario
Neurogenic orthostatic hypotension is defined here as a systolic blood pressure decrease of at least 20 mm Hg, or a diastolic blood pressure decrease of at least 10 mm Hg, within 3 minutes of moving from supine to standing — without the compensatory rise in heart rate expected in non-neurogenic forms.
Treatment approach
Management is pharmacologic, targeting two complementary mechanisms: expanding intravascular volume through a mineralocorticoid agonist, and increasing peripheral vascular resistance using pressor agents — with additional strategies for postprandial hypotension. The full protocol specifies agent selection, sequencing, and monitoring considerations.
References
DOI: 10.1212/cont.0000000000001598
- Features of autonomic dysfunction may include neurogenic orthostatic hypotension (a systolic blood pressure decrease by at least 20 mm Hg or diastolic blood pressure decrease by at least 10 mm Hg within 3 minutes from being supine to standing or by a tilt-table test without a compensated increase in heart rate [less than 0.5 beats/min in every mm Hg decrease in systolic blood pressure]).
- Approaches to expanding intravascular volume include the intake of two teaspoons of salt a day (corresponding to 11 g to 12 g of sodium chloride), 2 L to 2.5 L of water a day, and the mineralocorticoid agonist fludrocortisone of 0.1 mg orally 1 to 2 times a day.
- Methods of increasing peripheral vascular resistance include the use of pressor agents such as the α-adrenergic agonist midodrine (gradually titrating up to 10 mg orally 3 times a day with a reduced last dose if needed because of the risk of supine hypertension), the noradrenaline precursor droxidopa (gradually titrating up to 600 mg orally 3 times a day if needed), the noradrenaline reuptake inhibitor atomoxetine (18 mg orally 1 time a day), and the cholinesterase inhibitor pyridostigmine (60 mg orally 1 time a day).
- Having smaller but more frequent meals; reducing carbohydrates; or taking octreotide, acarbose, or caffeine 30 minutes before meals can improve postprandial hypotension.
View source ↗